EEM Rewind: Cam Berg's C Diff Pathway

Clostridioides difficile is a clinical syndrome, not just a positive stool test. Chronic watery diarrhea, recent antibiotics or hospitalization, immunosuppression, and even proton pump inhibitor exposure all change pretest probability, while PCR-toxin discordance often identifies colonization rather than active infection.

C difficile diagnosis and testing

• Syndrome over positive test: C difficile should be suspected in prolonged diarrhea with compatible risk factors, not in every loose stool; hyperacute illness is less typical, and symptoms often persist for weeks before testing is worth pursuing.
• Proton pump inhibitor risk: PPI exposure is a meaningful C difficile risk factor, and that elevated risk can persist for up to 1 year after the drug is stopped.
• Two step stool testing: PCR is highly sensitive but poor at separating infection from colonization, so a follow-up toxin EIA is what distinguishes active disease from an asymptomatic carrier state.
• Carrier versus active disease: PCR positive and EIA negative patients are usually colonized rather than infected; isolate them, but antibiotics are generally unnecessary. We walk through the practical interpretation in the chapter.
• Retesting after recent infection: PCR can remain positive long after appropriate treatment, so repeat testing soon after a known infection may mislead more than it helps.
• Immunosuppression as exception: Immunosuppressed patients are the main group where a PCR positive, EIA negative result may still represent true disease, so clinical judgment may favor treatment despite discordant testing.

C difficile treatment decisions

• Oral vancomycin first line: Oral vancomycin is the preferred initial therapy because metronidazole resistance has eroded confidence in older regimens.
• No role for IV vancomycin: IV vancomycin does not treat luminal C difficile because the drug needs to reach the gut directly, making the oral route the clinically relevant one.
• Empiric therapy restraint: Outside of a toxic hospitalized patient, empiric treatment is usually the wrong move; if no stool sample is available, it is reasonable to wait for a specimen rather than guess.
• Recurrent diarrhea after treatment: Recent treated C difficile complicates repeat testing because PCR may stay positive; there is a practical approach to suspected recurrence that relies more on clinical judgment than another swab. We get into that nuance in the episode.
• Enteric panel overuse: Reflex enteric pathogen panels are often low value in otherwise well patients with diarrhea, expensive, and prone to finding organisms that do not change management.

References:

1. Inghammar, Malin, et al. "Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection." Clinical Infectious Diseases 72.12 (2021): e1084-e1089.
2. Sheth, Prameet M., et al. "Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital." PloS one 14.2 (2019): e0207138.